Articles tagged with: CUDC-907

News»

[ by | Apr 5, 2016 3:08 pm | One Comment ]
Myeloma Morning: MorphoSys Sues, Claims Darzalex Infringes Patent; And CUDC-907

Good morning, myeloma world.

It's just Tuesday, and already the week is getting in­ter­est­ing. We'll be reporting on just two myeloma-related news items today, but one of them is the kind of news we don't see here at Myeloma Morning very often.

In particular, the German bio­tech com­pany MorphoSys has sued Janssen Biotech and Genmab, the two com­pa­nies that have devel­oped and mar­keted Darzalex (dara­tu­mu­mab). MorphoSys contends that sales of Darzalex infringe on a MorphoSys patent.

In addi­tion, we report on a study that came out last …

Read the full story »

News»

[ by | Jun 7, 2015 1:15 pm | Comments Off ]
ASCO 2015 Multiple Myeloma Update – Poster Presentations: Potential New Myeloma Therapies

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a num­ber of poster pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

During “poster sessions” at conferences such as the ASCO meeting, re­search re­­sults are made avail­able for review by meeting attendees in the form of posters, each of which summarizes the re­­sults of a single study. Each poster is typ­i­cally about two feet high by three or four feet in length, and all posters during a ses­sion are dis­played throughout a large conference hall.

Most of the myeloma-related …

Read the full story »

News»

[ by | Nov 15, 2013 10:52 pm | 3 Comments ]
ASH 2013 Preview: The Newest Multiple Myeloma Treatments On The Horizon

At this year’s American Society of Hematology (ASH) meeting, which will be held in early De­cem­ber, more than 100 oral pre­sen­ta­tions and about 400 poster pre­sen­ta­tions will summarize re­search focused on multiple myeloma.

Abstracts for these pre­sen­ta­tions are now avail­able.

During the next several weeks, The Beacon will pub­lish a series of arti­cles pre­viewing the myeloma-related studies from the ASH meeting that are of par­tic­u­lar interest.

Each of the articles will cover abstracts related to a specific topic, such as new treat­ments under de­vel­op­ment, current treat­ments, stem cell trans­plan­ta­tion, prog­nos­tic factors, and …

Read the full story »

NewsFlash »

[ by | Jan 21, 2013 12:52 pm | One Comment ]

GDC-0941 May Be Active In Multiple Myeloma – Results of a recent pre­clinical study suggest that the investigational drug GDC-0941, which is being developed by the biotech company Genentech, may have anti-myeloma activity and may increase the activity of Revlimid (lenalidomide) and dexa­methasone (Decadron). Like perifosine, another investigational myeloma treatment, GDC-0941 inhibits an enzyme in cancer cells known as phos­pho­inositide 3-kinase (PI3K). By in­hibit­ing PI3K, GDC-0941 disrupts the cell division cycle and causes cancer cell death. It is being investigated as a treatment for a variety of different cancers, including breast cancer and lung cancer. Based on their findings, the re­searchers recommend that GDC-0941 be further developed as a potential treatment for myeloma. For more information, please see the study in the journal Oncogene (abstract).

Phase 1 Clinical Trial To Study CUDC-907 In Multiple Myeloma And Lymphoma Patients – The pharma­ceutical company Curis (NASDAQ:CRIS) has launched a Phase 1 trial of CUDC-907 in patients with relapsed and refractory multiple myeloma or lymphoma. Patients must have received at least two prior thera­pies to be eligible for the study. CUDC-907 is a multi-targeted agent that inhibits both PI3K and histone deacetylase (HDAC) in cancer cells. Other HDAC inhibitors that are being investigated as potential treat­ments for multiple myeloma include Zolinza (vorinostat), panobinostat, and ricolinostat (ACY-1215). For more information, including trial locations, please see the clinical trial description.

LLS Teleconference About Latest Myeloma Research From ASH – On January 29, the Leukemia & Lym­phoma Society (LLS) will sponsor a free teleconference call about the latest myeloma research from the American Society of Hematology (ASH) annual meeting.  Dr. Kenneth Anderson, director of the Jerome Lipper Myeloma Center at the Dana-Farber Cancer Institute in Boston, will lead the program, which will run from noon till 1:30 p.m. Eastern Time.  Dr. Anderson will speak about current and emerging myeloma treatments, the role of clinical trials in the development of myeloma treatment, and advances in the management of treatment side effects. For more information or to register, please see the LLS website.